Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to replace painful liver biopsies with ultrasound and blood tests

NCT ID NCT07172997

Knowledge-focused Sponsor: Royal College of Surgeons in Ireland - Medical University of Bahrain Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 163 obese patients undergoing bariatric surgery to see if non-invasive tools like ultrasound and blood markers can accurately diagnose fatty liver disease (MASLD) and predict diabetes remission. Researchers will compare these tests to liver biopsy results before and after surgery. The goal is to develop a scoring system that avoids the need for invasive biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bariatric Surgery
What this could lead to
If successful, this could replace invasive liver biopsies with simple ultrasound and blood tests for diagnosing liver disease in obese patients, and help predict diabetes remission after weight-loss surgery.
What could go wrong
This is an observational study, not a treatment trial. The results may not apply to non-bariatric patients or other populations. The scoring system needs further validation before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 163 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Bahraini adult obese patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult obese patients undergoing bariatric surgery in KHUH surgery department consented to be included in the study. Exclusion Criteria: * Patients fail to complete the surgery due to intra-operative complications. * Patients fail to retrieve liver biopsy sample from due to intra-operative difficulties. * Patients with missing data pre-operatively * Body Mass Index less than 30 kg/m2. * Post-liver transplant patients * Patients known to have any liver disease other than MASLD * Patients with history of Alcohol Drinking.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASLD Non-alcoholic fatty liver disease (NAFLD) Obesity T2DM (type 2 diabetes mellitus)

Contacts and locations

Locations

  • Alhakeem Radiology Center

    Manama, Manama, 2901, Bahrain

  • King Hamad University Hospital

    Al Muharraq, Muharraq, Bahrain

More trials for these conditions

Other studies related to the condition(s) this trial covers.